These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 24944260)

  • 1. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
    Kaufmann H; Freeman R; Biaggioni I; Low P; Pedder S; Hewitt LA; Mauney J; Feirtag M; Mathias CJ;
    Neurology; 2014 Jul; 83(4):328-35. PubMed ID: 24944260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I; Freeman R; Mathias CJ; Low P; Hewitt LA; Kaufmann H;
    Hypertension; 2015 Jan; 65(1):101-7. PubMed ID: 25350981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA; Isaacson S; Lisk JP; Hewitt LA; Rowse G
    Mov Disord; 2015 Apr; 30(5):646-54. PubMed ID: 25487613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    Isaacson S; Vernino S; Ziemann A; Rowse GJ; Kalu U; White WB
    J Am Soc Hypertens; 2016 Oct; 10(10):755-762. PubMed ID: 27614923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
    Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
    Biaggioni I; Arthur Hewitt L; Rowse GJ; Kaufmann H
    BMC Neurol; 2017 May; 17(1):90. PubMed ID: 28494751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
    Isaacson S; Shill HA; Vernino S; Ziemann A; Rowse GJ
    J Parkinsons Dis; 2016 Oct; 6(4):751-759. PubMed ID: 27636856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
    Hauser RA; Hewitt LA; Isaacson S
    J Parkinsons Dis; 2014; 4(1):57-65. PubMed ID: 24326693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
    Isaacson SH; Skettini J
    Vasc Health Risk Manag; 2014; 10():169-76. PubMed ID: 24729712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA; Norcliffe-Kaufmann L; Martinez J; Kaufmann H
    Neurology; 2018 Oct; 91(16):e1539-e1544. PubMed ID: 30232253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    François C; Rowse GJ; Hewitt LA; Vo P; Hauser RA
    BMC Neurol; 2016 Aug; 16(1):143. PubMed ID: 27538531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
    Elgebaly A; Abdelazeim B; Mattar O; Gadelkarim M; Salah R; Negida A
    Clin Auton Res; 2016 Jun; 26(3):171-80. PubMed ID: 26951135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM
    Drugs; 2015 Feb; 75(2):197-206. PubMed ID: 25559422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
    Kaufmann H
    Clin Auton Res; 2008 Mar; 18 Suppl 1():19-24. PubMed ID: 18368303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H; Saadia D; Voustianiouk A; Goldstein DS; Holmes C; Yahr MD; Nardin R; Freeman R
    Circulation; 2003 Aug; 108(6):724-8. PubMed ID: 12885750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease.
    Hauser RA; Biaggioni I; Hewitt LA; Vernino S
    Mov Disord Clin Pract; 2018; 5(6):627-634. PubMed ID: 30637284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
    Freeman R; Landsberg L; Young J
    Neurology; 1999 Dec; 53(9):2151-7. PubMed ID: 10599797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
    Pérez-Lloret S; Quarracino C; Otero-Losada M; Rascol O
    Expert Opin Pharmacother; 2019 Apr; 20(6):635-645. PubMed ID: 30730771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
    François C; Hauser RA; Aballéa S; Dorey J; Kharitonova E; Hewitt LA
    J Med Econ; 2016; 19(5):515-25. PubMed ID: 26710315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent unexplained chest pain and dyspnea in a patient with coronary artery disease: a case report.
    Mobarek SK
    BMC Cardiovasc Disord; 2020 Feb; 20(1):54. PubMed ID: 32019498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.